In this episode of Bioprocessing Unfiltered, Jack Prior, head of process monitoring and data science and AI strategy at Sanofi, explores how AI has evolved from early expert systems to machine learning, generative AI, and agentic AI, and what that means for biomanufacturing today. He explains why digital transformation has not automatically created usable data, and why the real challenge is turning fragmented information from manufacturing systems into accessible, authentic, and analysis-ready data. Jack shares a practical framework for assessing data maturity and argues that the biggest near-term opportunity for AI is reducing friction in data engineering, troubleshooting, tech transfer, and decision support across bioprocessing organizations.

Links from this episode:
Bioprocessing Summit
Sanofi

Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

Anurag Rathore, professor of chemical engineering at the Indian Institute of Technology Delhi, joins Bioprocessing Unfiltered with host Alois Jungbauer to discuss his long career in advancing bioprocessing engineering. Rathore shares his thoughts on chromatography, using platform processes to accelerate process development, how infinity capture can be a way to arrive at platform processes, and if there is a need for alternative methods. He also explores updates needed to the traditional curriculum of biochemical engineering—and if the next generation should know how to use AI and ML—and his view on bioprocess and development.

Links from this episode:

Bioprocessing Summit
Indian Institute of Technology Delhi

Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.

At the most recent Bioprocessing Summit, David Y. H. Chang, CEO of Taiwan Bio-Manufacturing Company; Bo Wiinberg, Chief Business Development Officer of Novo Nordisk Foundation Cellerator; and Paul Lewus, Vice President of Site Operations at Amgen gathered for a fireside chat moderated by Ran Zheng, former CEO of Landmark Bio, to discuss the technologies and innovations shaping the future of biomanufacturing. The conversation explored upcoming trends, investment opportunities, and modalities into the next decade, as well as the question: how should the industry best prepare for all of it?

Links from this episode:
Bioprocessing Summit
Landmark Bio
Novo Nordisk Foundation Cellerator
Taiwan Bio-Manufacturing Company (TBMC)
Amgen

Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.